Met Life Investment Management, LLC Cti Biopharma Corp Transaction History

Met Life Investment Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2024	BUY	$4.2 - $6.01 $204,489 - $292,614	48,688 New	48,688 $204 Million
Q2 2022 May 10, 2024	BUY	$3.55 - $6.27 $172,842 - $305,273	48,688 New	48,688 $290,000
Q2 2022 Aug 11, 2022	BUY	$3.55 - $6.27 $172,842 - $305,273	48,688 New	48,688 $291,000
Q3 2018 Nov 14, 2018	SELL	$1.72 - $5.24 $47,253 - $143,958	-27,473 Closed	0 $0
Q2 2018 Aug 15, 2018	BUY	$3.81 - $5.26 $104,672 - $144,507	27,473 New	27,473 $137,000

Ticker CTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,385,000
Market Cap $1.04B
Description
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Met Life Investment Management, LLC with notifications on news.